PharmaCielo Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

PharmaCielo şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-2.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-2.9%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PCLO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PCLO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

PharmaCielo Piyasaya Karşı Temettü Getirisi

PCLO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PCLO)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.1%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (PCLO) (3 yıla kadar)	n/a

Önemli Temettü: PCLO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PCLO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PCLO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PCLO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

PharmaCielo Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Market cap size

Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.023 loss in 2Q 2023)

PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding

PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding

PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024

Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.034 loss in 3Q 2022)

PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.023 loss in 2Q 2022)

Pharmacielo Ltd. Appoints Marc Lustig as CEO

PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding

CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock.

New minor risk - Share price stability

First quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.019 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.096 loss per share (vs CA$0.18 loss in FY 2021)

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Independent Lead Director recently bought CA$83k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.034 loss per share (vs CA$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.049 loss in 2Q 2021)

PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt

Less than half of directors are independent

PharmaCielo Ltd. Announces Board and Executive Changes

CEO, President & Chairman of the Board recently bought CA$67k worth of stock

PharmaCielo Ltd., Annual General Meeting, Sep 01, 2022

CEO, President & Chairman of the Board exercised options to buy CA$87k worth of stock.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Full year 2021 earnings: Revenues miss analyst expectations

High number of new directors

Independent Lead Director recently bought CA$92k worth of stock

Independent Lead Director recently bought CA$292k worth of stock

PharmaCielo Ltd. announced that it expects to receive CAD 15 million in funding

Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?

Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Lead Director recently bought CA$1.8m worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

CEO, President & Director Henning von Koss has left the company

Pharmacielo Ltd. Provides Revenue Guidance for the Second Half of 2021

Second quarter 2021 earnings released

Independent Chairman of the Board Simon Langelier has left the company

Chief Financial Officer Scott Laitinen has left the company

First quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.064 loss in 1Q 2020)

Is PharmaCielo (CVE:PCLO) A Risky Investment?

Independent Director recently bought CA$115k worth of stock

Third quarter 2020 earnings released: CA$0.083 loss per share (vs CA$0.04 loss in 3Q 2019)

PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate

Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?

New 90-day high: CA$2.68

PharmaCielo Provides Update on GMP Compliance Process

PharmaCielo Ltd. Announces the Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

CEO, President & Director recently sold CA$88k worth of stock

New 90-day high: CA$2.18

PharmaCielo Ltd., PharmaCielo Colombia Holdings S.A.S. Enter into Strategic Alliance with AssuredTrans Inc

Revenue and earnings miss expectations

Pharmacielo Ltd. Announces Step Down of David Attard as Board Member, Effective December 1, 2020

PharmaCielo Ltd. Delivers Its First Commercial Shipment of Medicinal Grade CBD Isolate

New 90-day high: CA$0.74

PharmaCielo Ltd. Announces the First Harvest Cycle of Six High-THC Cultivars

PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding

PharmaCielo Ltd. Appoints Marc Lustig as Lead Director

PharmaCielo Ltd. Expands Portfolio of Cannabis Extracts to Meet Global B2b Medical-Grade Market Demand

New 90-day low: CA$0.54

New 90-day low - CA$0.55

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin